Also discussed are the hot new thing in funding and startups tackling the female grooming space.
Today, we’re talking about OrbiMed, beer, drug R&D, future unicorns, and more:
- 9 future pharma unicorns
- Have we hit peak craft brew?
- Forget mega-deals. Kingmaker deals ($1B+) are the hot new thing.
- The companies cropping up in the cannabis industry
- Female shaving startups
- AI for drug R&D
9 future pharma unicorns
Want to predict the next big names in pharma? A good place to start is the portfolios of investors with recent $1B+ exits. Looking at these investors’ common bets reveals 9 pharma companies to watch.
Note: you should pay attention to our picks. In 2015, we detailed 50 future unicorns in partnership with The New York Times. Today, 19 of the 50 (38%) have gone on to become unicorns. More to come on this.
Using company search, we pulled all 26 pharmaceutical companies that have IPO’d, or were acquired, for more than $1B since 2013. We then mapped their investors using the Business Social Graph.